NCT01513733已完成1 期
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer
Andrew J. Armstrong, MD2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Number of participants who experience dose limiting toxicities at the highest titrated dose for each dose level
研究概览
简要总结
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features;
- •At least 18 years of age when signing the Informed Consent;
- •Presence of metastatic disease on bone scan or CT/MRI imaging;
- •Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration);
- •For patients who have not had an orchiectomy, there must be a plan to maintain effective GnRH-analogue therapy for the duration of the trial;
- •Serum testosterone level < 50 ng/dL at the Screening Visit;
- •Progressive disease on or following docetaxel-based chemotherapy with medical or surgical castration. Patients who are intolerant of docetaxel are also allowed. Disease progression for study entry is defined as one or more of the following three criteria: 1) PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 μg/L (2 ng/mL); 2) Soft tissue disease progression defined by RECIST 1.1; 3) Bone metastatic disease progression defined by one or more new lesions on bone scan that are not clinically consistent with tumor flare;
- •No more than three prior chemotherapy regimens with at least one regimen containing docetaxel (unless intolerant as per # 7 above);
- •Karnofsky Performance Status of >70;
- •Estimated life expectancy of at least three months;
- •Able to swallow the study drug and comply with study requirements;
- •Willing and able to give informed consent.
排除标准
- •Subjects > 80 years old (dose escalation phase only, due to lower clearance in elderly patients);
- •Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment;
- •Metastases in the brain or active epidural disease (NOTE: patients with treated epidural disease are allowed provided follow up imaging documents stability of epidural disease);
- •Absolute neutrophil count < 1,200/μL, platelet count < 100,000/μL, and hemoglobin <9 g/dL at the Screening Visit; (NOTE: patients may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the Screening Visit)
- •Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal at the Screening Visit;
- •Creatinine > 1.5 x ULN at the Screening visit;
- •History of another malignancy within the previous 3 years other than non-melanomatous skin cancer or non-invasive bladder cancer treated with curative intent;
- •Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide, MDV3100), 5-α reductase inhibitors (finasteride, dutasteride), estrogens (ie DES), sipuleucel-T, or chemotherapy within 28 days of Day 1 visit or plans to initiate treatment with any of these treatments during the study;
- •Use of herbal products that may decrease PSA levels or systemic corticosteroids greater than the equivalent of 10 mg of prednisone/prednisolone per day within four weeks of Day 1 visit;
- •Ongoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4
- •Exposure to ketoconazole or other strong CYP3A4 inhibitors or inducers intravenously or orally within 28 days prior to Day 1 Visit. For abiraterone acetate or TAK700, 14 days washout is needed.
- •Ongoing treatment with sensitive CYP1A2 substrates or CYP1A2 substrates with narrow therapeutic range (Appendix 3).
- •Ongoing treatment with CYP3A4 substrates with narrow therapeutic range (Appendix 3).
- •Radiation therapy within 2 weeks (if single fraction of radiotherapy within 2 weeks) and radionuclide therapy within 8 weeks of Day 1 visit;
- •Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery;
- •Structurally unstable bone lesions suggesting impending fracture;
- •Clinically significant cardiovascular disease including:myocardial infarction within 6 months, uncontrolled angina within 3 months, congestive heart failure, Diagnosed or suspected congenital long QT syndrome; significant ventricular arrhythmias, Prolonged corrected QT interval by the Fridericia or Bazett correction formula, History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; Hypotension (systolic blood pressure < 86 mMHg or bradycardia with a heart rate < 50 beats per minute on any ECG taken at the Screening or Day 1 visit; Uncontrolled hypertension; TIA or stroke/CVA within 6 months of Day 1 visit; Rest limb claudication or ischemia within 6 months of Day 1 visit
- •Use of an investigational agent within four weeks of Day 1 visit or plans to initiate treatment with an investigational agent during the study;
- •Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last three months);
- •Major surgery within four weeks prior to Day 1 visit.
- •Presence of NCI CTC grade >1 peripheral neuropathy
- •History of pancreatitis
- •Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host).
- •Chronic hepatitis B or C with advanced, decompensated hepatic disease, or cirrhosis of the liver or history of a chronic viral hepatitis or known viral hepatitis carrier (patients recovered from hepatitis will be allowed to enter the study).
- •Documented prior disease progression on tasquinimod -
研究组 & 干预措施
Tasquinimod single dose
Experimental
干预措施: tasquinimod (Drug)
tasquinimod 0.25 mg followed by 0.5 mg
Experimental
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
干预措施: tasquinimod 0.25 mg; 0.5 mg (Drug)
tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Experimental
tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
干预措施: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg (Drug)
结局指标
主要结局
Number of participants who experience dose limiting toxicities at the highest titrated dose for each dose level
时间窗: 6 weeks
The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
次要结局
- Evaluation of progression free survival(Every 9 weeks)
- Preliminary evidence of response efficacy as measured by the rates of PSA decline (waterfall plot) and benchmarks of reaching a >30% decline within 3 months, a PSA decline >50% and >90%, and PSA normalization. Duration of PSA responses will be measured(Every 3 weeks)
- Evaluation of overall response(Every 9 weeks)
- Favorable changes in circulating tumor cell number (5 or greater to less than 5) and proportion of men who achieve a reduction in CTC count(Every 3 weeks)
- Detailed characterization of all NCI CTC v4.0 toxicities over time (per cycle)(Every 3 weeks)
- The concentration of tasquinimod and cabazitaxel in blood plasma(12 weeks)
- Number and percent of participants that are alive(2 years)
- Pain response, as measured by percentage of patients with a reduction of at least 2 points on the visual analog scale despite a stable pain regimen. Pain scores over time will be described in an exploratory fashion.(Every 3 weeks)
- Changes in bone alkaline phosphatase and LDH over time(Every 3 weeks)
研究者
Andrew J. Armstrong, MD
Assoc Professor of Medicine
Duke University
研究点 (2)
Loading locations...
相似试验
终止
2 期
Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideMetastatic Prostate CancerNCT03764540Centre hospitalier de l'Université de Montréal (CHUM)57
已完成
2 期
A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate CancerMetastatic Castration Resistant Prostate CancerNCT01541007Jeffrey Yachnin M.D., PhD.100
Unknown
2 期
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based ChemotherapyProstate CancerCastration-resistant Prostate CancerNCT03356912Consorzio Oncotech220
已完成
2 期
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells KineticProstate CarcinomaCastration-resistant Prostate CancerCirculating Tumor CellsChemotherapyNCT03101046UNICANCER40
已完成
1 期
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate CancerProstate CancerNCT00574769University of Southern California27